1,140
Views
2
CrossRef citations to date
0
Altmetric
Letter to the Editor

Serum uric acid: a mediator of cardio-reno-metabolic diseases

&
Pages 1127-1128 | Received 15 Dec 2021, Accepted 17 Dec 2021, Published online: 31 Dec 2021

References

  • Gulab A, Torres R, Pelayo J, et al. Uric acid as a cardiorenal mediator: pathogenesis and mechanistic insights. Expert Rev Cardiovasc Ther. 2021;19(6):547–556.
  • Katsiki N, Athyros VG, Karagiannis A, et al. Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk? Curr Vasc Pharmacol. 2011;9(6):698–705.
  • Wei F, Li J, Chen C, et al. Higher serum uric acid level predicts non-alcoholic fatty liver disease: a 4-year prospective cohort study. Front Endocrinol (Lausanne). 2020;11:179.
  • Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: an update. Metabolism. 2016;65(8):1109–1123.
  • Katsiki N, Perez-Martinez P, Anagnostis P, et al. Is nonalcoholic fatty liver disease indeed the hepatic manifestation of metabolic syndrome? Curr Vasc Pharmacol. 2018;16(3):219–227.
  • Heda R, Yazawa M, Shi M, et al. Non-alcoholic fatty liver and chronic kidney disease: retrospect, introspect, and prospect. World J Gastroenterol. 2021;27(17):1864–1882.
  • Cojocariu C, Singeap AM, Girleanu I, et al. Nonalcoholic fatty liver disease-related chronic kidney disease. Can J Gastroenterol Hepatol. 2020;2020:6630296.
  • Katsiki N, Mikhailidis DP. Abnormal peri-organ or intra-organ fat deposition and vascular risk. Angiology. 2018;69(10):841–842.
  • D’Marco L, Puchades MJ, Panizo N, et al. Cardiorenal fat: a cardiovascular risk factor with implications in chronic kidney disease. Front Med (Lausanne). 2021;8:640814.
  • D’Marco L, Salazar J, Cortez M, et al. Perirenal fat thickness is associated with metabolic risk factors in patients with chronic kidney disease. Kidney Res Clin Pract. 2019;38(3):365–372.
  • Derosa G, Maffioli P, Ž R, et al. Impact of statin therapy on plasma uric acid concentrations: a systematic review and meta-analysis. Drugs. 2016;76(9):947–956.
  • Katsiki N, Athyros VG, Karagiannis A, et al. The role of statins in the treatment of type 2 diabetes mellitus: an update. Curr Pharm Des. 2014;20(22):3665–3674.
  • Katsiki N, Dimitriadis GD, Mikhailidis DP. Serum uric acid and diabetes: from pathophysiology to cardiovascular disease. Curr Pharm Des. 2021 Jan 4;27:1941–1951. Epub ahead of print.
  • Inzucchi SE, Zinman B, Fitchett D, et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care. 2018;41(2):356–363.
  • Mazidi M, Katsiki N, Mikhailidis DP, et al.; Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group. Associations of serum uric acid with total and cause-specific mortality: findings from individuals and pooling prospective studies. Atherosclerosis. 2020;296:49–58.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.